Topical Tacrolimus versus Hydrocortisone on Atopic Dermatitis in Paediatric Patients: A Randomized Controlled Trial.

医学 特应性皮炎 湿疹面积及严重程度指数 他克莫司 随机对照试验 过敏性 过敏 随机化 体表面积 皮质类固醇 皮肤病科 儿科 内科学 哮喘 免疫学 移植
作者
M F Rahman,A. Nandi,Soodeh Kabir,Mohamed Kamal,Basher Ms,Laila Anjuman Banu
出处
期刊:PubMed 卷期号:24 (3): 457-63 被引量:10
链接
标识
摘要

Atopic dermatitis (AD) is a chronic, inflammatory skin disease in early childhood. Atopic dermatitis is familial disease, often coexists with other atopic diseases with multiple risk factors associated with atopic eczema. The disease is more frequent in urban areas compared with rural areas. Changes in nutrition and a decrease in infant breast-feeding and respiratory allergies are contributory factors for the condition. A Randomized Controlled Trial (RCT) was carried to compare the efficacy and safety of Tacrolimus ointment with a topical corticosteroid reference therapy. A total 60 patients aged between 2 to 10 years, having atopic dermatitis for at least one year and comply Hanifin-Rajka criteria were selected using random number table and allocated into study and control groups through randomization. Study group was treated with topical Tacrolimus 0.03% twice daily for three weeks, while the control group was treated with 1% Hydrocortisone acetate for the same period. Both groups had a washed out phase for 2 weeks with a follow up period of 6 weeks. Eczema Area and Severity lndex (EASI) was assessed at baseline and three weeks after treatment. Efficacy was evaluated at each visit by six clinical signs of atopic dermatitis through measurement of the affected surface area and the EASI score in each of four body regions. Before intervention, in study group mean EASI score was 11.29 with a SD of 2.14, while in control group it was 11.05 with a SD of 2.46. Difference was statistically insignificant (p>0.05). At the end of the treatment, in study group mean EASI score was 4.86 with a SD of 1.01, while in control group it was 7.97 with a SD of 1.80. Statistically high significant difference was observed between EASI scores of two groups before and after the treatment (p<0.001). After getting treatment with Tacrolimus, median reduction of EASI score was 56.07 in study group, while getting treatment with Hydrocortisone, median reduction of EASI score was 27.16. Difference was highly significant (p<0.001). It is evidenced that Tacrolimus ointment (0.03%) acts as an effective as well as safe non-steroidal topical therapy for the treatment of dermatitis in paediatric patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
MRu发布了新的文献求助50
刚刚
刚刚
多情的续完成签到,获得积分10
刚刚
刚刚
1秒前
堂吉诃德发布了新的文献求助10
1秒前
1秒前
天冬完成签到,获得积分20
2秒前
3秒前
跳跃的小林完成签到,获得积分10
3秒前
江逾白完成签到,获得积分10
4秒前
柏达完成签到,获得积分20
4秒前
ttt发布了新的文献求助10
5秒前
5秒前
6秒前
王冉冉完成签到,获得积分20
6秒前
7秒前
2哇哇哇发布了新的文献求助10
7秒前
浮游应助超级yang采纳,获得10
7秒前
Moweikang发布了新的文献求助10
8秒前
李哈哈发布了新的文献求助10
9秒前
10秒前
Manzia完成签到,获得积分10
11秒前
duoduoqian发布了新的文献求助10
12秒前
13秒前
快到碗里来完成签到,获得积分10
13秒前
天天快乐应助王赟晖采纳,获得10
13秒前
打打应助王赟晖采纳,获得10
13秒前
华仔应助王赟晖采纳,获得10
14秒前
深情安青应助王赟晖采纳,获得10
14秒前
英俊的铭应助王赟晖采纳,获得10
14秒前
ding应助王赟晖采纳,获得10
14秒前
斯文败类应助王赟晖采纳,获得10
14秒前
Lucas应助xuan采纳,获得10
14秒前
思源应助王赟晖采纳,获得10
14秒前
CodeCraft应助王赟晖采纳,获得10
14秒前
李爱国应助王赟晖采纳,获得10
14秒前
玉铡完成签到,获得积分20
14秒前
2哇哇哇完成签到,获得积分10
15秒前
十七。完成签到,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
A Half Century of the Sonogashira Reaction 1000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
The Social Work Ethics Casebook: Cases and Commentary (revised 2nd ed.).. Frederic G. Reamer 600
Extreme ultraviolet pellicle cooling by hydrogen gas flow (Conference Presentation) 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 500
A Manual for the Identification of Plant Seeds and Fruits : Second revised edition 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5170255
求助须知:如何正确求助?哪些是违规求助? 4361071
关于积分的说明 13578323
捐赠科研通 4208230
什么是DOI,文献DOI怎么找? 2308001
邀请新用户注册赠送积分活动 1307435
关于科研通互助平台的介绍 1254240